Dohj LLC Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Dohj LLC increased its holdings in Regeneron Pharmaceuticals by 105.1% during the second quarter, owning a total of 1,208 shares valued at approximately $634,000.
• Several institutional investors, including Vanguard Group and Goldman Sachs Group, have also recently made significant investments in Regeneron, reflecting strong institutional interest with 83.31% of shares owned by such investors.
• Analysts have mixed ratings on Regeneron Pharmaceuticals, with three ratings of Strong Buy, eighteen Buy ratings, and a current average target price of $817.67.

Dohj LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 105.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,208 shares of the biopharmaceutical company's stock after purchasing an additional 619 shares during the period. Dohj LLC's holdings in Regeneron Pharmaceuticals were worth $634,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of REGN. Vanguard Group Inc. raised its position in shares of Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock worth $5,966,767,000 after acquiring an additional 121,545 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Regeneron Pharmaceuticals by 4.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock valued at $1,379,467,000 after buying an additional 89,579 shares in the last quarter. Amundi raised its stake in Regeneron Pharmaceuticals by 3.4% during the first quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company's stock valued at $979,794,000 after buying an additional 52,166 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 18.0% in the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock worth $724,984,000 after acquiring an additional 174,056 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 2.1% during the first quarter. American Century Companies Inc. now owns 722,467 shares of the biopharmaceutical company's stock valued at $458,211,000 after acquiring an additional 14,921 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on REGN. Argus downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 price objective for the company. Canaccord Genuity Group restated a "buy" rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Weiss Ratings reissued a "hold (c-)" rating on shares of Regeneron Pharmaceuticals in a research report on Saturday, September 27th. Finally, Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target for the company. in a research note on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Trading Down 0.4%

Shares of NASDAQ:REGN opened at $583.24 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The business's 50-day moving average is $573.16 and its 200 day moving average is $566.16. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,024.36. The firm has a market capitalization of $61.82 billion, a P/E ratio of 14.70, a P/E/G ratio of 1.87 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The company had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm's revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $11.56 EPS. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.